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Background: Patients who present with abnormal liver function tests (LFTs) in primary care and no obvious symptoms can be difficult to manage.  
Objective: To follow-up a cohort of liver function tested patients to determine their outcome.
Design: Population-based retrospective cohort study.
Setting: Tayside, Scotland from 1989 to 2003.
Subject: Patients with no clinically obvious liver disease at initial liver function testing in primary care.
Main outcomes: Diagnosed liver disease, mortality.
Methods:  Record-linkage of databases ascertained risk factors and outcomes. Measures of performance were calculated and Weibull regression analysis from initial LFT date was performed on all outcomes by level of abnormality. 
Results: 95,977 patients had 364,194 incident initial LFTs, with median follow-up 3.7 years. 21.7% had at least one abnormal LFT and 1108 (1.15%) developed liver disease. Elevated transaminase was strongly associated with diagnosed liver disease, HR=4.23 (95% CI 3.55, 5.04) for mild levels and HR=12.67 (9.74, 16.47) for severe levels vs. normal. For GGT these hazards were 2.54 (2.17, 2.96) and 13.44 (10.71, 16.87) respectively. Low albumin was strongly associated with all-cause mortality, HR=2.65 (2.47, 2.85) for mild levels and HR=4.99 (4.26, 5.84) for severe levels. Sensitivity for predicting events over 5 years was low and specificity high.
Conclusions: All LFTs were predictive markers for liver disease as well as general ill health, although sensitivity was poor. Most patients with abnormal LFTs had no later formal diagnosis of liver disease within the study period. The time taken to develop liver disease in these patients provides opportunity to intervene. 
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Introduction

Liver function tests (LFTs) are widely performed opportunistically in primary and secondary care, even in patients without suspected liver disease, and may trigger further invasive and expensive investigations. When patients present with abnormal liver function tests (LFTs) in primary care with no clinically obvious liver disease, the appropriate level of follow-up to take can be unclear. As a result GPs may over-investigate some and under-investigate others leading to variation in clinical practice. Increasing the number of tests will increase the likelihood of false positive results.1 However, despite the increasing use of LFTs, patients continue to present with potentially fatal complications of undiagnosed end stage liver disease, which may have been preventable through earlier diagnosis. 

Most of the published epidemiological studies report only the prevalence of liver disorders rather than addressing the absolute or relative risks of subsequent liver disease following abnormal LFTs.2-5 Previous studies have established that ALF may be indicative of neoplasms as well as liver disease and are associated with poor outcome.6-8  In many cases this may be due to causes that could be intervened with earlier resulting in reduced morbidity and mortality.9








The study population was initially derived from a laboratory database which contained all electronically available LFT results from patients in the Tayside region of Scotland, UK during the fifteen year period from 1989 to 2003. Tayside is a mixed urban/rural region characteristic of Scotland with a population of approximately 410,000. LFTs included bilirubin, albumin, alkaline phosphatase (Alk Phos), gamma-glutamyl transferase (GGT), alanine transaminase (ALT) and aspartate aminotransferase (AST). Since many laboratories only measure either ALT or AST these two tests were combined in this study and are referred to as transaminases.

In brief, patients aged 16 and above with no obvious clinical signs and symptoms of liver disease, with at least two initial LFTs referred from a Tayside GP between 1989 and 2003 were eligible for inclusion. Exclusion criteria detailed elsewhere ensured that the study population of patients had no clinically recognised liver disease at presentation in primary care.10

Databases
Data were extracted by the Health Informatics Centre (HIC).11 The databases relevant to this study, listed below, covered the entire study period and were used within procedures approved under the Data Protection Act and Caldicott Guardian.  

1.	Death registry from the General Register Office (GRO) for Scotland including causes of death.
2.	Carstairs score for deprivation.12 The score was divided into two categories of affluent and deprived. 
3.	Regional biochemistry database. All LFTs came from the largest hospital laboratory in the region, Ninewell’s. Two smaller hospital laboratories contributed electronic LFT results later, one from 1998 and the other from 2003.
4.	SMR01 database: Holds hospital admissions and procedures for all hospitals in Scotland. Major comorbidity groups were identified using this database and Diabetes Audit and Research Tayside Scotland (DARTS) and Heart disease Evidence-based Audit and Research Tayside Scotland (HEARTS) databases for diabetes and CHD respectively.13 
5.	SMR02 database: Patient records of maternal inpatient and day case episodes allowing identification of women who had their LFTs measured during pregnancy.
6.	SMR04 database:  Holds all inpatient and day case episodes for mental health specialties, which identified patients admitted/discharged with diagnoses of alcohol dependency or drug misuse.
7.	Primary care prescription database: Holds encashed prescriptions in Tayside, and allowed identification of patients on some hepatotoxic drugs including statins, antibiotics and NSAIDs.
8.	Epidemiology of Liver Disease In Tayside (ELDIT) database: Contains all Tayside patients with liver diseases that have been ‘electronically’ diagnosed using record-linkage of biomedical datasets, including virology and immunology.14,15

All of the electronic databases described above were electronically linked with a unique identifier, the community health index (CHI).16 The CHI is used for all health encounters in Tayside for the population registered with a general practice. 
 
Outcomes
The primary outcomes following the initial LFT results were all-cause mortality, liver mortality and liver disease diagnosis. For descriptive purposes other outcomes including hospital admission, diagnosis of IHD, cancer, respiratory disease, diabetes and biliary disease were tabulated. The individual liver disease outcomes were also recorded by LFT (Appendix 1).

Statistical Analysis
Normal, mildly elevated and severely elevated categories were defined for each LFT using regional laboratory standard cut-offs which vary by age and sex for some tests (10). Severely elevated was defined as 2.5 times the normal range. Baseline characteristics were tabulated by level of abnormality for each test. These characteristics were age, gender, Carstairs category, comorbidities during the period 1980 to study start (including cancer, diabetes, IHD and respiratory disease and biliary disease), alcohol dependency and drug misuse (from hospitalisations), methadone abuse, pregnancy, and the use of statins, NSAIDs or antibiotics in the three months before LFTs.  

Outcomes from the initial LFTs were tabulated. Sensitivity, specificity, positive predictive value (PPV) and negative predictive values (NPV) of the LFTs to diagnose liver disease and to predict death (any cause and liver caused) were calculated over one and five years. Since some patients did not have all their LFTs tested, liver disease diagnosis by LFT testing can be subject to selection bias. The predicted probability of testing for each LFT was found by fitting a logistic regression model adjusted for all the predictors mentioned above.17,18 The probability of testing was then used to weight the logistic regression models for predicting outcome.  





Before exclusions, we extracted LFTs from 310,511 patients. When we excluded patients under the age of 16, non-Tayside residents and those who had their initial abnormal LFTs measured in secondary care, 99,165 patients were left. When the remaining exclusion criteria were applied (bilirubin >35 μmol/L i.e. clinically obvious liver disease, complications within 6 weeks and history of liver disease) our study population contained 95,977 patients with 364,194 incident initial LFTs taken in primary care. The median follow-up time was 3.7 years (IQR 1.4, 7.6). 57.9% of patients were female and the median age was 54.6 years (IQR 39.2, 68.8). Alk phos was measured in 99.2% of patients, albumin (99.2%), bilirubin (93.6%), transaminases (76.5%) and GGT (10.9%). Use of LFTs in primary care increased over time due to a combination of more testing and better laboratory coverage. At initial tests, 21.7% of patients had at least one abnormal LFT. 

Baseline characteristics
The mean age of patients with abnormal LFTs ranged from 48.8 to 52.6 years except for albumin which had a mean age of 69.6. Of those with GGT measured, a higher proportion were male and deprived patients – more so than any other LFT (table 1). Abnormal GGT groups also had the highest percentage of patients dependent on alcohol (15.3%), drugs (0.9%) and methadone (0.7%). Patients with abnormal albumin had much more comorbidity compared to the other LFTs (table 1). The percentage of patients with initially abnormal LFTs prescribed statins in the three months beforehand was less than those with normal LFTs. The percentage of patients prescribed NSAIDs or antibiotics in the preceding three months was highest in those with lowered albumin.

Outcomes
Table 2 contains the outcomes per 1000 patient years (TPY) by initial LFT level. Low albumin had much higher rates of mortality from any cause compared to the other LFTs with rates of 166.3 TPY and 260.4 TPY for mildly and severely elevated respectively. Severe alk phos had the next highest death rate of 99.8 TPY. For liver caused mortality, severely elevated GGT had the highest rate of 9.8 TPY followed by alk phos (8.43 TPY) and albumin (8.19 TPY). Albumin also had the highest rates for cancer diagnosis – for mild and severe they were 56.6 and 96.0 TPY respectively. Transaminase and GGT were most associated with liver diagnoses, with severely abnormal levels having rates of 36.3 TPY and 41.0 TPY respectively. Rates of hospital admission after an abnormal albumin test were extremely high with even a mildly lowered result having a rate over 500 TPY.

Performance measures
For outcomes of all-cause mortality, liver mortality and liver disease diagnosis, GGT had the best sensitivity scores (0.769 and 0.714 for liver mortality over one and five years respectively) (see Table 3). However, all the tests had generally low sensitivity. Albumin had the poorest sensitivity overall however its specificity was the highest (0.980 for liver disease). All LFTs had NPVs of 0.990 or more for all outcomes except all-cause mortality. All tests had very low PPVs between 0.002 and 0.052 for all outcomes except all-cause mortality, for which albumin had the highest PPV (0.508 within five years).

Survival analysis
Liver disease diagnosis: All the LFTs were significantly predictive of liver disease even after adjusting for risk factors for liver damage (see table 4). Of the mildly elevated LFTs, transaminase had the highest hazard ratio of 4.23 (95% CI 3.55, 5.04) (see Figure 1a). All severely elevated LFTs had hazard ratios over 8, with alk phos highest followed by GGT and transaminase. Other factors predictive of liver disease were older age, deprivation, alcohol dependency, illicit drug use and methadone use. For the transaminase model the hazards for the latter three factors were 4.48 (95% CI 3.70, 5.42), 2.25 (95% CI 1.51, 3.36) and 4.52 (95% CI 3.07, 6.65) respectively. 

Liver disease mortality: Of the mildly abnormal LFTs, low albumin had the highest hazard for liver mortality of 7.38 (95% CI 4.60, 11.81). Severely elevated GGT had the highest hazard ratio overall with a value of 25.32 (95% CI 15.27, 41.97), followed by alk phos and albumin (see Table 4). The only baseline factors which predicted liver disease mortality were gender, older age, Carstairs score (deprived) and alcohol dependency. Alcohol dependency had hazards as high as 10.84 (95% CI 7.28, 16.14) for the albumin adjusted model. 





The most striking observations of this study are that: 1) liver disease is not common in those with abnormal LFTs over a median follow-up time of 3.7 years, 2) GGT shows highest sensitivity for liver disease above other LFTs and is a good predictor of liver disease and liver mortality after adjustment for the bias of selective testing and 3) abnormal LFTs are predictive of death from non-hepatic causes (particularly albumin).

This is the first large-scale population-based analysis of LFTs with a long follow-up period and complete determination of outcome. These results are derived from unselected “real-world” observations in a geographically defined population.  However, liver disease can suffer from under ascertainment as hospital discharge records and death certificates often omit liver disease if it was not the primary cause of death.  We have no precise data on the reasons why LFTs were requested and these are likely to include the investigation of suspected liver disease, monitoring of disease or treatment where liver toxicity may occur and for the investigation of non-specific illness. However, we were able to identify patients with a history of major comorbidities since 1980, including cancer, diabetes and IHD using hospital admission records, and patients who were prescribed statins, NSAIDs and antibiotics in the three months before their initial LFTs.  The other limitations of electronic data sources are that we have no information on alcohol intake, BMI or other anthropometry associated with Non-alcoholic fatty liver disease (NAFLD).  Scotland has recently developed software which enables extraction of Read coded data from primary care systems which will enable us to address this issue in future prospective studies.20  However, as regards this study, electronic primary care data would not be available for all patients from 1989 since not all practices would have stored electronic data back then.

Diagnosis of liver disease in the study population was identified throughout the study period using the ELDIT database.14  ELDIT was created via the record-linkage of various datasets.  These include those SMR hospital admission databases described in the methods, the SMR06 cancer registry which contains all malignant neoplasms and carcinomas in-situ of the liver, and hospital datasets containing virology, immunology, pathology, and endoscopy information.16  Each liver disease was electronically diagnosed using strict algorithms.14 15  Since most major liver diseases are diagnosed in secondary care, it is assumed that the ELDIT database would catch more disease than a primary care clinical database.

We found that the sensitivity of LFTs in detecting liver disease is generally poor whilst in contrast specificity was high. In terms of prediction of future liver disease NPV was high whilst PPV was low. A study in Italy found sensitivity and specificity values for ALT of 0.40 and 0.98 respectively for hepatitis C, which were quite similar to ours for any liver disease.21 Survival models showed that all the tests have high hazard ratios relating to outcomes of liver disease and mortality from liver disease. Of 667 people who had a severely elevated transaminase over 11% where diagnosed with chronic liver disease, and a mild elevation of the test had a high hazard for developing chronic liver disease of over 4 suggesting that transaminase may be a good predictor. 

In Tayside for much of the duration of this study, GGT was not routinely requested as part of the ‘batch of LFTs’. This explains the low numbers of GGTs performed, and it is not surprising that the baseline characteristics of patients for GGT results differed from the other tests. It was the only test requested more frequently for males, illicit drug users and patients living in deprived areas suggesting that GPs selected these patients for GGT testing. The patients not tested for GGT had their GGT results imputed using the ‘gold standard’ multiple imputation technique.19 Even after this, severely abnormal GGT increases the risk of liver disease over 13 times compared to normal GGT and 2.5 times if mildly abnormal. This suggests strongly that GGT provides additional information over the other LFTs and should be considered as an important and informative part of the LFTs. In light of this finding the practice by some laboratories of not routinely measuring GGT should be reviewed. 

Why is the sensitivity of LFTs for liver disease so poor?  Of those who subsequently develop liver disease their first LFT may be normal. The study in Korea found that patients with slightly raised transaminases, which were still in the normal range, developed liver disease and suggests an adjustment of the normal limit.7 Also many patients with abnormal LFTs detected in this study may have had no subsequent formal diagnosis of liver disease because of a lack of investigation and a limited time interval to develop complications. So that it is possible that there is a pool of undiagnosed liver disease within this cohort. It is likely on epidemiological grounds, that the majority of these abnormalities could be attributable to undiagnosed alcohol related liver disease, Hepatitis C or NAFLD. The fact that this group of patients did not come to harm during the study is reassuring. However, the study follow-up period is medium term (median of 3.7 years) compared to the natural history of these diseases. It does however illustrate a window of opportunity to intervene in these patients with life style advice, alcohol intake reduction and therapies for drug abuse. 

All-cause mortality is a much more common outcome in this study than liver disease. This suggests that these tests may be better markers of poor health than liver disease, thus possibly justifying the increasing use of LFTs as a screen for general illness. In particular reduced albumin levels are associated with serious illness,22-24 as substantiated by the fact that even a mildly reduced albumin level has a hazard of mortality over two and a half times that of the normal. This raises uncertainty over what the most appropriate investigation for patients with abnormal LFTs is if most do not have underlying liver disease but have increased risks of several other diagnoses e.g. cancer and cardiovascular disease. Indeed, it may be the case that undiagnosed underlying liver disease is a risk factor for death from other causes.

In summary, this study has described the epidemiological association of abnormalities in an initial primary care panel of LFTs with important health outcomes. Until now the strength of the association with death or liver disease in patients with abnormal levels of LFTs was not known. Further work is planned to develop more predictive models for clinical decision support and conduct cost-effectiveness analyses on LFTs referred from primary care to ascertain the optimal management strategies that will reduce costs to the health service and optimize patient care. 
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Table 1 Baseline and historical characteristics of the population (n=95977) by LFT (normal/abnormal)
Baseline Characteristics	Population (%)		Albumin (%)		Alkaline phosphatase (%)		Transaminase (%)		GGT (%)		Bilirubin (%)
	(N=95977)		Normal(n=93240)	Abnormal(n=1947)		Normal(n=85329)	Abnormal(n=9928)		Normal(n=68314)	Abnormal(n=5107)		Normal(n=8861)	Abnormal(n=1623)		Normal(n=83457)	Mildly elevated(n=6365)




























































































































Table 3 Percentage sensitivity, specificity, PPV and NPV of LFTs at the first GP consultation in patients with no obvious liver disease for 1 and 5 year periods

LFT	Performance	All death		Liver death		Liver disease





















1 The sensitivity and ppv for bilirubin only includes patients with bilirubin ≤35 at initial GP consultation.
Note: All performance measures were adjusted for the probability of testing.17


Table 4 Weibull regression model results by level of initial LFT abnormality (vs normal) for time to liver disease, all cause mortality and liver disease mortality

Variable	Liver disease		All cause mortality		Liver disease mortality
	Hazard ratio (95% CI)		Hazard ratio (95% CI)		Hazard ratio (95% CI)
Albumin 					
	Mildly lowered	3.41 (2.55, 4.55)		2.65 (2.47, 2.85)		7.38 (4.60, 11.81)
	Severely lowered	8.48 (5.04, 14.28)		4.99 (4.26, 5.84)		16.17 (6.41, 40.81)
Alkaline phosphatase					
	Mildly elevated	2.91 (2.49, 3.39)		1.80 (1.69, 1.91)		3.81 (2.72, 5.32)
	Severely elevated	14.42 (10.20, 20.37)		2.88 (2.44, 3.40)		17.81 (9.20, 34.49)
Transaminase1 					
	Mildly elevated	4.23 (3.55, 5.04)		1.35 (1.26, 1.44)		5.41 (3.80, 7.71)
	Severely elevated	12.67 (9.74, 16.47)		1.88 (1.58, 2.23)		7.17 (3.75, 13.70)
GGT1					
	Mildly elevated	2.54 (2.17, 2.96)		1.56 (1.48, 1.63)		4.89 (3.43, 6.99)
	Severely elevated	13.44 (10.71, 16.87)		2.90 (2.61, 3.23)		25.32 (15.27, 41.97)
Bilirubin2					
	Mildly elevated	2.02 (1.68, 2.44)		1.20 (1.12, 1.29)		3.89 (2.76, 5.48)

Notes: 	Weibull models were fitted separately for each LFT and were adjusted for all baseline factors described in the text.  
1 The missing data from transaminase and GGT were imputed using a multiple imputation method for the modelling.







Figure 1. Survival by level of abnormality from: a) first transaminase test to liver disease diagnosis; b) first albumin test to all cause mortality































